GB1603153A - Creation of Inventions and Patents with Artificial Intelligence

GB1603153A – Protein and process for its production
– Google Patents

GB1603153A – Protein and process for its production
– Google Patents
Protein and process for its production

Download PDF
Info

Publication number
GB1603153A

GB1603153A
GB16259/78A
GB1625978A
GB1603153A
GB 1603153 A
GB1603153 A
GB 1603153A
GB 16259/78 A
GB16259/78 A
GB 16259/78A
GB 1625978 A
GB1625978 A
GB 1625978A
GB 1603153 A
GB1603153 A
GB 1603153A
Authority
GB
United Kingdom
Prior art keywords
protein
solution
salt
concentration
precipitated
Prior art date
1977-04-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired

Application number
GB16259/78A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Siemens Healthcare Diagnostics GmbH Germany

Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1977-04-25
Filing date
1978-04-25
Publication date
1981-11-18

1978-04-25
Application filed by Behringwerke AG
filed
Critical
Behringwerke AG

1981-11-18
Publication of GB1603153A
publication
Critical
patent/GB1603153A/en

Status
Expired
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

G—PHYSICS

G01—MEASURING; TESTING

G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES

G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 – G01N31/00

G01N33/48—Biological material, e.g. blood, urine; Haemocytometers

G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

G01N33/531—Production of immunochemical test materials

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates

C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC

Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof

Y10S530/806—Antigenic peptides or proteins

Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC

Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof

Y10S530/827—Proteins from mammals or birds

Y10S530/829—Blood

Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC

Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof

Y10S530/827—Proteins from mammals or birds

Y10S530/829—Blood

Y10S530/83—Plasma; serum

Description

PATENT SPECIFICATION ( 11) 1 603 153
on ( 21) Application No 16259/78 ( 22) Filed 25 Apr 1978 ( 19) U) ( 31) Convention Application No 2718326 ( 32) Filed 25 Apr 1977 in ( 33) Fed Rep of Germany (DE) ( 44) Complete Specification Published 18 Nov 1981 ( 51) INT CL 3 C 07 G 7/00 ( 52) Index at Acceptance C 3 H 100 110 120 130 FZ ( 54) A PROTEIN AND PROCESS FOR ITS PRODUCTION ( 71) We, BEHRINGWERKE AKTIENGESELLSCHAFT, a body corporate organised according to the laws of the Federal Republic of Germany, of Marburg/Lahn, Federal Republic of Germany, do hereby declare the invention for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described
in and by the following statement:-
The present invention relates to a protein, to a process for its isolation and to its use for the manufacture of antisera directed against it.
It is known that the lysate of human erythrocytes contains, in addition to its main constituent, i e haemoglobin, a great number of enzymes, the enzyme activity of which has been thoroughly investigated Among these enzymes are carboanhydrase B, carboanhyd 10 rase C, superoxide dismutase, catalase, lactate dehydrogenase, glutathione reductase, acidic phosphatase, glucose-6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase, glucose-6-phosphatisomerase, phosphoglucomutase, phosphoglycerate kinase, adenylate kinase, as well as a protein which performs the three enzyme activities of 2,3-diphosphoglycerate mutase, 2,3-di-phosphoglycerate phosphatase and phospho 15 glycerometase Some of these enzymes have been isolated.
The present invention provides a protein which is characterised by a) a protein content of 99 % + 1 % by weight, essentially consisting of samino-acids, 20b) a carbohydrate content of 1 % 0 5 % by weight, 20 c) a sedimentation coefficient C=O S of 6 88 + 0 505, w d) especially a molecular weight of 160,000 15,000, 25 e) an isoelectric point within the p H range 5 5 0 2, f) an electrophoretic mobility in the range of the P,-globulins of human serum, g) a specific immunological reaction with an antibody specifically directed against the protein.
By the consideration of the most outstanding properties of the protein, i e, its molecular size amd mobility, it can be designated a 7 S-P 3globulin 30 A remarkable feature of the protein of the invention is that it can be proved immunologically to be present in a stroma-free lysate of human erythrocytes and in an amount of about 1 % by weight of the protein content, on the basis of the cell content of red blood corpuscles In comparison with haemoglobin and carboanhydrase B, the new protein ranks in third place with regard to the quantity present.
The characteristic features of the protein were determined as follows.
Determination of the sedimentation coefficient was carried out in an analytical ultracentrifuge at 56,000 rev /min in double sector cells in a superposing cell as described by Vinograd, Proc Acad Sci USA 49,902 ( 1963) The absorption band was at 280 nm and the migration in the superposition cell was measured Distilled water having a p H-value of 40 7.0 was used as the solvent and the protein concentrations used were 10, 7 5 and 2 5 mg/100 ml solutions.
The molecular weight was calculated by the use of two different methods A value of 160,000 15,000 was found via the determination of the sedimentation equilibrium as described by Yphantis The second method gave a value for the molecular weight by the 45 1,603,153 determination of the protein in a 1 % (weight by volume) sodium dodecyl sulphatecontaining carrier gel, which consisted of polyacrylamide, with a human placenta lactogen and a human albumin as the reference substances The value given was 45, 000 5,000.
From this discrepancy it can be assumed that the molecule is built up from four equal or very similar subunits 5 The molecular weight may also be determined with the aid of analytical column chromatography with a cross-linked dextran as the carrier, for example Sephadex G 150 of Messrs Pharmacia (“Sephadex” is a Trade Mark) By this method the protein of the invention is eluted with immunoglobulin A and the C 3-component of the complement system using 0 01 M phosphate buffer having a p H of 7 0 and using human serum as the 10 reference substance This gives a value for the molecular weight of about 160,000 to 180,000 If the elution buffer is combined with 1 M Na Cl, a substance having a molecular weight of about 40,000 is obtained This corresponds to the electrophoretically determined subunits of the protein of the invention.
For the determination of the isoelectric point, the method of isoelectric focussing was 15 used, employing the devices and reagents marketed for this purpose by Messrs LKB Stockholm.
The electrophoretic mobility was determined using cellulose acetate as carrier matrix with a barbital Na buffer having a p H value of 8 6.
The carbohydrates were determined by a method described by Schultze, Schmidtberger, 20 Haupt, Biochem Z ( 1958) 329, 490.
The amino-acid analysis was carried out by a method described by Moore, Spakman, Stein, Anal Chem ( 1958), 30,1185, which uses a liquid chromatograph It was found that aspartic acid and glutamic acid were the a-amino acids most frequently occurring in the peptide chain 25 The immunological characterisation of the substance was effected simply according to a described diffusion process in which the antigen, i e the protein, and an antibody which is directed against the protein, or a crude antiserum containing such antibodies, were allowed to diffuse toward each other in a carrier medium, for example in agar Where a suitable proportion of both reaction components met, a visible precipitate was formed In view of 30 this finding it can be seen that there can be used any immunological technique for detecting or determining the protein as well as the antibodies directed against this protein An antiserum which has a high specificity against the protein of the invention can be obtained according to known processes, i e processes which are in actual use in the att or described in the literature of the art, for example by the immunisation of vertebrate animals, 35 especially rabbits, with the isolated protein By such a method, for example, the animals are immunised over a period of several weeks using an immunological adjuvant, for example complete Freunds’ adjuvant Blood of the immunised animals is then withdrawn, the serum separated therefrom and, if desired, the antibody-rich gamma-globulin fraction isolated By means of this serum or antibody preparation, the protein of the invention can also be 40 isolated quantitatively, for example by the electroimmunoassay described by Laurell, Analyt Biochem ( 1966) 15,45.
The present invention also provides a process for the isolation of the above-described protein, which comprises subjecting a solution or suspension comprising the protein, preferably a lysate of erythrocytes to one or more fractionation methods suitable for 45 fractionating a protein of the invention, and isolating the fraction(s) comprising the protein.
The process is advantageously one wherein a liquid comprising the protein is subjected to one or more of the following measures, carried out in any order:
a) addition of a neutral salt until the protein of the invention is precipitated, b) addition of an organic solvent until the protein of the invention is precipitated, 50 c) addition of a water-soluble salt of an acridine or quinoline base until the protein of the invention is precipitated, d) addition of an organic acid until the protein of the invention is precipitated, e) reduction of the electrical conductivity until the protein of the invention is precipitated, 55 f) adsorption of the protein of the invention on an anion exchanger and selective elution therefrom, g) preparative zone electrophoresis with isolation of the zone of the proteins which migrate in the P-range, h) molecular sieve fractionation for isolating a fraction with a molecular weight of about 60 150,000.
In each case, the fraction(s) comprising the protein of the invention is or are isolated These steps are discussed in more detail below.
a) The protein of the invention can be precipitated from a 1 % aqueous solution by the addition of a neutral salt, preferably ammonium sulphate in a concentration of between 1 5 65 1,603,153 and 2 moles/l at a neutral p H.
b) The protein of the invention can be precipitated by the addition of an organic solvent, for example by adding ethanol in a concentration of 10 % by volume, to an aqueous solution having a weakly acid p H-value, for example in a 0 04 molar acetate buffer having a p H of 5 5 at 00 C 5 c) It has been found that the protein of the invention can be precipitated by a water-soluble organic base of the acridine or quinoline series It is precipitated from its aqueous solution, for example, with 2-ethoxy-6,9-diamino acridine lactate in a concentration of 0 01 mole/l at a p H of 8 0.
d) The protein of the invention can be precipitated with an organic acid, for example 10 with trichloroacetic acid up to a concentration of 0 2 mole/l, especially at a concentration of 0.2 mole/l I, or with a perchloric acid up to a concentration of 0 6 mole/I, especially at a concentration of 0 6 mole/l.
e) The protein of the invention can be precipitated by the reduction of the electrical conductivity of the protein solution in a weakly acid range, for example by dialysis against 15 distilled water having a p H of 5 0.
f) The charge properties of the protein make fractionation possible using an anion exchanger Basic anion exchangers, preferably those which contain diethylaminoethyl or triethylaminoethyl groups, or quaternary bases or their derivatives, as functional groups, especially with a cellulose matrix, bind the protein from a relatively low concentration in a 20 buffer solution This adsorption can be prevented by increasing the salt concentration.
However where this behaviour is known, the protein can be adsorbed and eluted using a salt solution of a higher concentration, or a buffer solution of a greater p H.
g) Because of its electrophoretic mobility, preparative zone electrophoresis may be used to advantage for the enrichment or isolation of the protein of the invention During 25 electrophoresis the protein migrates in the P,-range of the plasmaproteins from which it can then be isolated.
The immunological affinity of the protein to its antibodies may be used for enriching the protein by means of immunoadsorption processes For this purpose, an immunoadsorbant that is capable of specifically binding the protein i e a carrier-bound antibody, may be 30 prepared in a manner known per se The protein can then be eluted from the immunoadsorbant by a modification of the medium.
h) The knowledge of the molecular weight of the protein permits the use of a method which leads to the isolation or enrichment of a substance having a molecular weight of 150,000, preferably the method of gel-filtration or ultrafiltration The fraction obtained by 35 ion exchange chromatography which contains the protein can be advantageously separated on a molecular sieve The individual fractions obtained by the separation are collected and analysed immunochemically Only those fractions wherein there is a large proportion of the protein of the invention are isolated.
By the selection and use of one or more of the above methods, the enrichment of the 40 protein and its separation from the remaining accompanying proteins in a solution or suspension which comprises a protein of the invention, may be carried out.
In addition to these possible methods for isolating the protein of the invention, we now have found a further process which is surprisingly very simple and which is preferentially used to isolate this protein This method is detailed below 45 The protein is adsorbed from an aqueous solution or suspension thereof at a low electrical conductivity of between 1 and 10 pu S/cm, preferably of between 2 5 and 2 8 p.S/cm, on an anion exchanger, preferably on an diethylaminoethyl ion exchanger, at a p H value around the neutral point (p H 6 5 7 5) The charged adsorbant is separated from the remaining solution, suitably in a chromatography column, treated with a salt solution 50 having an increasing concentration (a linear salt gradient) and the eluate is then collected in fractions The individual fractions are analysed immunochemically and those fractions which react with antibodies directed against the protein of the invention are collected The salt solutions mentioned here are neutral salt solutions and buffer solutions The linear salt gradient for the elution increases from 10 p S/cm to about 55 m S/cm.
The isolated protein fractions are stored suitably at temperatures of below O C, preferably in a deep frozen state.
As described above, the isolated protein migrates uniformly with a mobility corresponding to that of the p,-globulins of human serum Where polyacrylamide gel electrophoresis is 60 used to isolate the product, product heterogenieity occurs: Two bands are found in the gel.
Closer investigation has shown that this heterogenieity is due to a dissociation of the protein during its preparation This dissociation can be prevented by adding a proteinase inhibitor for example the trypsin callicrein inhibitor isolated from animal lungs; in other words, proteinases, for example plasmin or callicrein provoke a modification of the native protein 65 1,603,153 and this modification can be prevented by the addition of proteinase inhibitors.
During the isolation of the protein it is preferable to add a proteinase inhibitor, suitably a polyvalent proteinase inhibitor, in a quantity which is sufficient for proteinase inhibition, to the aqueous solutions used.
In an electrolyte-free solution or suspension, the isolated protein shows a tendency to 5 forming aggregates These give a sedimentation coefficient of about 11 0 S in an ultracentrifuge Where the salt concentration is increased, for example to a value of 0 25 M/1 Na Ci or 025 M/l phosphate, the native protein component reverts to its natural form.
Further increasing the electrolyte concentration to an ion strength of O 5 1 0, for example by the addition of sodium chloride, causes the protein to dissociate into subunits which have 10 a sedimentation coefficient of about 3 0 S With an ion strength of lL = 0 15, the native molecule reverts to its natural form The degree of dissociation is also dependent, however, on the concentration of the total proteins in the solution or suspension At a low protein concentration, for example < 1 %, the 3 S-proportion is predominant. The native molecule is most stable in a salt solution having an ion strength of between p 15 = 0 01 and 0 2. The starting material for the isolation of the protein of the invention is, for example, red blood cells i e erythrocytes They are generally lysed by being introduced into a hypotonic medium; the lysis is suitably effected with distilled water In order to prevent a proteolytic attack of the enzymes present in the lysate, a polyvalent proteinase inhibitor can be added 20 to the lytic agent prior to the addition of the cells, for example to the distilled water The lysis is advantageously carried out at a weakly acid p H-value, for example at a p H-value between 5 5 and 6 0. The particular components of the erythrocytes are generally separated from the hemolysate after about 10 to 30 hours It is advisable to use high speed centrifugation for 25 this purpose; the stroma-free supernatant obtained may then be used for the preparation of the protein of the invention This solution can be treated with an ion exchanger and a molecular sieve as described above, whereafter the protein determined in the individual fractions may be further worked up or finally isolated. Extracts from blood rich organs, for example from the placenta, are also suitable as 30 starting materials for the isolation of the protein. The protein can be obtained, of course, by a method or combination of methods as described hereinbefore by due consideration of the precipitation properties thereof. The protein of the invention is a valuable diagnostic agent It is particularly suitable for the preparation of antisera according to the methods known for this purpose 35 Accordingly the invention also provides antibodies, generally in the form of an antiserum, directed against the protein of the invention and a process for their preparation. The invention further provides a method of determining the protein of the invention, which comprises subjecting a sample of the liquid to a qualitative or quantitative immunological determination using as the antibody component antibodies of the invention, 40 especially in the form of an antiserum. The invention is illustrated by the following Example. EXAMPLE 2 1 of packed red blood cells were washed three times each time with 2 1 of physiological 45 Na CI solution For hemolysis 4 times the volume of distilled water was added 10 mg of a proteinase inhibitor from bovine lungs (Antagosan of Behringwerke AG, Marburg, "Antagosan" being a Trade Mark) are added per litre of hemolysate The p H was adjusted to a value of 5 8 with IN of acetic acid, whilst stirring After standing overnight at 4 6 C, the stroma which had flocked out were removed by high speed centrifugation at 19,000 50 rpm The p H was then adjusted to a value of 6 8 with 1 N sodium hydroxide solution The electrical conductivity was then measured as being 2 7 m S/cm. 1000 g (weight in the wet state) of diethylaminoethyl cellulose in granular form was added to the stroma-free lysate and this was stirred intensively for 1 hour Then, the adsorbant charged with protein was collected on a Buchner filter and washed until free from 55 hemoglobin with 0 005 M phosphate buffer (p H 6 8) which contained, per litre, 10 mg of the above-mentioned proteinase inhibitor After introduction into a chromatography column, elution of the proteins was effected using a linear salt gradient of 5 litres of 0 005 M Na-phosphate buffer (p H 6 8) and 0 4 M of Na-phosphate buffer (p H 6 8) containing, per litre, 10 mg of Antagosan 60 The eluate was collected in 500 ml portions. Subsequently, characterisation of the fractions was carried out by polyacrylamide gel electrophoresis Those fractions which contained the main quantity of the 7 S-PI-globulin were mixed and concentrated by ultrafiltration On average, 40 ml of concentrate having a protein content of 5 5 % (weight/volume) were obtained 65 1,603,153 For gel-filtration, the concentrate was introduced into a column filled with Sephadex G ("Sephadex" being a Trade Mark of Pharmacia, Uppsala), which was equilibrated with 0.01 M phosphate buffer (p H 7 0) The eluate was collected in 40 ml fractions and were characterised as above in the polyacrylamide gel electrophoresis In the main peak the 7 S-03-globulin was eluted The fractions which seemed pure were mixed and concentrated 5 by ultra-filtration The concentrate of the 7 S-l 31-globulin was stored in a deep frozen state. The yield of protein from 2 litres of the packed red blood corpuscles was, on average, 1 5 g. The product obtained showed the following composition of amino acids and carbohydrates The error ranges due to analysis methods are also given below. Amino Acid Mol % Variation coefficient 10 % Lysine 6 68 2 67 Histidine 1 61 5 08 Arginine 5 05 397 15 Aspartic acid 11 39 1 21 Threonine 5 05 2 23 Serine 4 98 4 12 Glutamic acid 8 44 4 35 20 Proline 5 66 6 95 Glycine 9 13 2 22 Alanine 7 35 1 68 251/2 Cystine 1 65 2 04 Valine 8 96 1 36 25 Methionine 0 32 28 87 Isoleucine 4 84 1 17 Leucine 8 79 3 83 Tyrosine 3 34 4 24 30 Phenylalanine 5 92 3 81 Tryptophan 1 01 10 30 Carbohydrates % by weight 35 Hexoses (Gal/Man 1:1) 0 9 + 0 2 Acetylhexoseamine 0 3 + 0 1 Acetyl-neuraminic acid 0 Fucose 0 40 Claims (1) WHAT WE CLAIM IS:- 1 A protein which is characterised by a) a protein content of 99 % + 1 % by weight, b) a content of carbohydrates of 1 0 + 0 5 % by weight, 45 c) a sedimentation coefficient C= O S W of 6 88 -+ 0 5 S, d) a molecular weight of 160,000 + 15,000, 50 e) an iso-electric point within a p H range 5 5 + 0 2, f) an electrophoretic mobility in the range of the l,-globulins of human serum, g) a specific immunological reaction with an antibody specifically directed against the protein. 2 A protein as claimed in claim 1, which comprises four sub-units which are 55 characterised by a molecular weight of 45,000 + 5,000. 3 A protein as claimed in claim 1, substantially as described in the Example herein. 4 A process for the preparation of a protein as claimed in claim 1, which comprises subjecting a solution or suspension comprising the protein to one or more fractionation methods suitable for fractionating a protein as claimed in claim 1, and isolating the 60 fraction(s) comprising the protein claimed in claim 1. A process as claimed in claim 4 for the production of a protein as claimed in claim 1, wherein a liquid comprising the protein is subjected to one or more of the following measures, carried out in any order: a) addition of a neutral salt until the protein is precipitated, 65 1,603,153 _q 1,603,153 b) addition of an organic solvent until the protein is precipitated, c) addition of a water-soluble salt of an acridine or quinoline base until the protein is precipitated, d) addition of an organic acid until the protein is precipitated, e) reduction of the electrical conductivity until the protein is precipitated, 5 f) adsorption of the protein on an anion exchanger and selective elution therefrom, g) preparative zone electrophoresis with isolation of the zone of the proteins which migrate in the P 1-range, h) molecular sieve fractionation for isolating a fraction with a molecular weight of about 150,000 10 6 A process as claimed in claim 5, wherein the neutral salt is ammonium sulphate. 7 A process as claimed in claim 6, wherein the ammonium sulphate is used in a concentration of from 1 5 to 2 moles/litres. 8 A process as claimed in claim 6 or claim 7, wherein the protein is precipitated from a 1 % (w/v) aqueous solution 15 9 A process as claimed in any one of claims 5 to 8, wherein the organic solvent is ethanol. A process as claimed in claim 9, wherein 10 % (v/v) ethanol is admixed with a buffered solution comprising the protein at a temperature of O C. 11 A process as claimed in claim 10, wherein the buffer is 0 04 molar acetate buffer 20 having a p H of 5 5. 12 A process as claimed in any one of claims 5 to 11, wherein the watersoluble salt is of an acridine base. 13 A process as claimed in claim 12, wherein the salt is 2-ethoxy-6,9diamino acridine lactate 25 14 A process as claimed 12 or claim 13, wherein the acridine salt is in a concentration of 0 01 mole/I at a p H of 8 0. A process as claimed in any one of claims 5 to 14, wherein the organic acid is trichloroacetic acid. 16 A process as claimed in claim 15, wherein the trichloroacetic acid is used in a 30 concentration of 0 2 mole/I. 17 A process as claimed in any one of claims 5 to 14, wherein the organic acid is perchloric acid. 18 A process as claimed in claim 17, wherein the perchloric acid is used in a concentration of 0 6 mole/I 35 19 A process as claimed in any one of claims 14 to 18, wherein the reduction of electrical conductivity is by dialysis against distilled water. A process as claimed in claim 19, wherein the distilled water has a p H of 5 0. 21 A process as claimed in any one of claims 5 to 20, wherein the ion exchanger has functional groups of one or more of the following: diethylaminoethyl and triethylami 40 noethyl groups, and quaternary bases and derivatives thereof. 22 A process as claimed in claim 21, wherein the ion exchanger has a cellulose matrix. 23 A process as claimed in any one of claims 5 to 22, wherein the protein is eluted from the ion exchanger by means of an eluant having a higher salt concentration or a greater p H than the solution in which the protein was applied to the ion exchanger 45 24 A process as claimed in claim 5, wherein an aqueous solution comprising a protein as claimed in claim 1, which has an electrical conductivity of 1 10 lLS/cm is adsorbed onto an anion exchanger at a p H of between 6 5 and 7 5, separated from the supernatant and treated with a salt solution having an increasing concentration, the eluate collected in fractions and the protein isolated from the fractions in which it is contained 50 A process as claimed in claim 24, wherein the protein-containing solution or suspension has a conductivity within the range of from 2 5 to 2 8,S/cm. 26 A process as claimed in claim 24 or claim 25, wherein the ion exchanger is a diethylaminoethyl ion exchanger. 27 A process as claimed in any one of claims 24 to 26, wherein the salt solution is a 55 neutral salt solution or a buffer solution. 28 A process as claimed in any one of claims 24 to 27, wherein the increasing concentration is a linear salt gradient. 29 A process as claimed in claim 28, wherein the linear salt gradient rises from 10 lS/cm to 100 ms/cm 60 A process as claimed in any one of claims 4 to 29, wherein the protein solution used is the hemolysate of erythrocytes. 31 A process as claimed in any one of claims 4 to 30, wherein the resulting solution comprising the protein is stored at a temperature below O C. 32 A process as claimed in any one of claims 4 to 31, wherein the resulting solution 65 1,603,153 comprising the protein is concentrated and stored in a deep-frozen state. 33 A process as claimed in claim 4, carried out substantially as described in the Example herein. 34 A protein as claimed in claim 1, whenever prepared by a process as claimed in any one of claims 4 to 33 5 Antibodies directed against a protein as claimed in any one of claims 1 to 3 and claim 34. 36 Antibodies as claimed in claim 35, in the form of an antiserum. 37 A process for the production of antibodies as claimed in claim 35 or claim 36, which comprises administering a protein as claimed in any one of claims 1 to 3 and claim 34, to a 10 vertebrate animal, bleeding the animal after a suitable time has elapsed, and preparing antibodies or an antiserum from the antibody-containing blood. 38 A process as claimed in claim 37, wherein the animal is a rabbit. 39 A method of determining a protein as claimed in claim 1, in a liquid, which comprises subjecting a sample of the liquid to a qualitative or quantitative immunological 15 determination using the antibodies as claimed in claim 35 or claim 36. ABEL & IMRAY, Chartered Patent Agents, Northumberland House, 303-306 High Holborn, 20 London WC 1 V 7 LH Printed for Her Majesty's Stationery Office, by Croydon Printing Company Limited Croydon, Surrey, 1981. Published by The Patent Office 25 Southampton Buildings London, WC 2 A IAY, from which copies may be obtained. GB16259/78A 1977-04-25 1978-04-25 Protein and process for its production Expired GB1603153A (en) Applications Claiming Priority (1) Application Number Priority Date Filing Date Title DE19772718326 DE2718326A1 (en) 1977-04-25 1977-04-25 NEW PROTEIN AND METHOD FOR THE PRODUCTION THEREOF Publications (1) Publication Number Publication Date GB1603153A true GB1603153A (en) 1981-11-18 Family ID=6007198 Family Applications (1) Application Number Title Priority Date Filing Date GB16259/78A Expired GB1603153A (en) 1977-04-25 1978-04-25 Protein and process for its production Country Status (17) Country Link US (1) US4297274A (en) JP (1) JPS53133618A (en) AT (1) AT366062B (en) AU (1) AU516677B2 (en) BE (1) BE866355A (en) CA (1) CA1108535A (en) DE (1) DE2718326A1 (en) DK (1) DK176178A (en) ES (1) ES468932A1 (en) FR (1) FR2388825A1 (en) GB (1) GB1603153A (en) IE (1) IE46738B1 (en) IT (1) IT7822621D0 (en) LU (1) LU79511A1 (en) NL (1) NL7804365A (en) SE (1) SE7804713L (en) ZA (1) ZA782330B (en) Families Citing this family (8) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title DE3013724A1 (en) * 1980-04-10 1981-10-15 Behringwerke Ag, 3550 Marburg NEW PROTEIN PP (DOWN ARROW) 9 (DOWN ARROW), METHOD FOR ITS ENRICHMENT AND PRODUCTION AND ITS USE US4378509A (en) * 1980-07-10 1983-03-29 Motorola, Inc. Linearized digital phase and frequency detector JPS58500366A (en) * 1981-03-06 1983-03-10 セルテツク　リミテツド single clone antibody FR2548670B1 (en) * 1983-07-07 1985-10-25 Merieux Inst PROCESS FOR THE PREPARATION OF THE MAIN BLOOD HEMOLYSIS PROTEINS IN UNDENATURED FORM DE3334405A1 (en) * 1983-09-23 1985-04-04 Behringwerke Ag, 3550 Marburg MEMBRANE ASSOCIATED PROTEINS (MP (DOWN ARROW) 2 (DOWN ARROW)), METHOD FOR THEIR EXTRACTION AND USE DE3418888A1 (en) * 1984-05-21 1985-11-21 Behringwerke Ag, 3550 Marburg TISSUE PROTEIN PP (DOWN ARROW) 1 (DOWN ARROW) (DOWN ARROW) 8 (DOWN ARROW), METHOD FOR ITS DETERMINATION AND USE JPS6178726A (en) * 1984-09-27 1986-04-22 Asahi Medical Kk Purification of rheumatoid-specific protein EP2209490A4 (en) * 2007-11-14 2013-01-09 VGX Pharmaceuticals LLC Antibody production elicited by a dna vaccine delivered by electroporation Family Cites Families (7) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title US3931399A (en) * 1970-12-22 1976-01-06 Behringwerke Aktiengesellschaft Process for isolating a fibrin-stabilizing factor US3904751A (en) * 1970-12-22 1975-09-09 Behringwerke Ag Process for isolating a fibrin stabilizing factor from human placenta US4065445A (en) * 1971-09-29 1977-12-27 Behringwerke Aktiengesellschaft Pregnancy-specific β1 -glycoprotein and process for isolating it DE2221261A1 (en) * 1972-04-29 1973-11-15 Behringwerke Ag AP GLYCOPROTEINS AND PROCEDURES FOR THEIR ISOLATION DE2353973C3 (en) * 1973-10-27 1979-10-04 Behringwerke Ag, 3550 Marburg Steroid binding globulin and process for its manufacture US3910822A (en) * 1974-03-14 1975-10-07 Us Health Isolation of glucocerebrosidase from human placental tissue DE2445677C2 (en) * 1974-09-25 1982-09-16 Behringwerke Ag, 3550 Marburg High molecular weight alpha globulin and process for its production 1977 1977-04-25 DE DE19772718326 patent/DE2718326A1/en not_active Withdrawn 1978 1978-04-19 ES ES468932A patent/ES468932A1/en not_active Expired 1978-04-20 FR FR7811669A patent/FR2388825A1/en active Pending 1978-04-21 IT IT7822621A patent/IT7822621D0/en unknown 1978-04-24 AU AU35404/78A patent/AU516677B2/en not_active Expired 1978-04-24 NL NL7804365A patent/NL7804365A/en not_active Application Discontinuation 1978-04-24 AT AT0292578A patent/AT366062B/en not_active IP Right Cessation 1978-04-24 ZA ZA00782330A patent/ZA782330B/en unknown 1978-04-24 DK DK176178A patent/DK176178A/en not_active Application Discontinuation 1978-04-24 LU LU79511A patent/LU79511A1/en unknown 1978-04-24 IE IE802/78A patent/IE46738B1/en unknown 1978-04-24 CA CA301,838A patent/CA1108535A/en not_active Expired 1978-04-24 JP JP4920678A patent/JPS53133618A/en active Pending 1978-04-25 SE SE7804713A patent/SE7804713L/en unknown 1978-04-25 BE BE187093A patent/BE866355A/en unknown 1978-04-25 GB GB16259/78A patent/GB1603153A/en not_active Expired 1980 1980-03-07 US US06/128,253 patent/US4297274A/en not_active Expired - Lifetime Also Published As Publication number Publication date BE866355A (en) 1978-10-25 IE780802L (en) 1978-10-25 ATA292578A (en) 1981-07-15 LU79511A1 (en) 1978-11-28 ES468932A1 (en) 1978-12-16 SE7804713L (en) 1978-10-26 DK176178A (en) 1978-10-26 IT7822621D0 (en) 1978-04-21 AU516677B2 (en) 1981-06-18 JPS53133618A (en) 1978-11-21 CA1108535A (en) 1981-09-08 AU3540478A (en) 1979-11-01 US4297274A (en) 1981-10-27 NL7804365A (en) 1978-10-27 IE46738B1 (en) 1983-09-07 AT366062B (en) 1982-03-10 DE2718326A1 (en) 1978-10-26 ZA782330B (en) 1979-04-25 FR2388825A1 (en) 1978-11-24 Similar Documents Publication Publication Date Title Dunn et al. 1967 The α2-Macroglobulin of Human Plasma: I. ISOLATION AND COMPOSITION US4217339A (en) 1980-08-12 Glycoprotein and process for isolating it CA1183451A (en) 1985-03-05 Method for producing a csap tryptic peptide and anti- csap antibodies Bretting et al. 1976 Purification and characterization of the agglutinins from the sponge Axinella polypoides and a study of their combining sites Podack et al. 1976 Purification of the sixth and seventh component of human complement without loss of hemolytic activity Mahoney et al. 1978 Purification and physicochemical properties of β‐galactosidase from Kluyveromyces fragilis US4269825A (en) 1981-05-26 New glycoprotein and process for isolating it US4191533A (en) 1980-03-04 Pregnancy-specific β1 -glycoprotein and process for isolating it US4301064A (en) 1981-11-17 Ubiquitary tissue protein PP8 US4254021A (en) 1981-03-03 Tissue specific protein and process for preparing same US4302385A (en) 1981-11-24 Placenta-specific tissue protein PP10 US4500451A (en) 1985-02-19 New protein PP13 extracted from human placental tissues and use thereof US4468345A (en) 1984-08-28 Protein (PP17), a process for concentrating and isolating it and its use US4746731A (en) 1988-05-24 Isolated tissue protein PP18 GB1603153A (en) 1981-11-18 Protein and process for its production US4368148A (en) 1983-01-11 Protein PP9, process for its enrichment and its isolation and its use US4592863A (en) 1986-06-03 Protein PP20, a process for obtaining it, and its use US4325866A (en) 1982-04-20 Protein, PP11, a process for its preparation and its use Kuwano et al. 1978 PURIFICATION OF BOVINE PINEAL HYDROXYINDOLE O‐methylTRANSFERASE BY IMMUNOADSORPTION CHROMATOGRAPHY US4309339A (en) 1982-01-05 Leucine-rich 3,1-S-α2 -glycoprotein, process for isolating it and its use IL45931A (en) 1977-08-31 Steroid-binding globulin and process for preparing it van Oss et al. 1974 Isolation of human serum alpha-2 HS glycoprotein Lusis 1983 [44] Preparation of microsomal β-glucuronidase and its membrane anchor protein, egasyn Bohn et al. 1981 Placenta-specific tissue protein PP 10 Bohn et al. 1986 Protein PP 20, a process for obtaining it, and its use Legal Events Date Code Title Description 1982-02-10 PS Patent sealed [section 19, patents act 1949] 1983-12-14 PCNP Patent ceased through non-payment of renewal fee
Download PDF in English

None

Contact information